Drug Utilization Review (DUR) Meeting Minutes
December 5, 2018

Members Present: Katie Kram, Tanya Schmidt, LeNeika Roehrich, Andrea Honeyman, Jesse Rue, Peter Woodrow, Laura Schield, Michael Booth, Gaylord Kavlie

Members Absent: Zach Marty, Michael Quast, Jeffrey Hostetter, Russ Sobotta

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy, Gary Betting

Announcements
The North Dakota Medicaid DUR Board held an election for the open DUR Board Chair position at the start of the meeting. L. Roehrich was nominated and P. Woodrow made a motion to close the nomination proceedings with no voiced opposition. A voice vote was called with L. Roehrich elected as the DUR Board Chair by unanimous vote of the present DUR Board members.

Old Business
Chair L. Roehrich called the meeting to order at 1:09 p.m. Chair L. Roehrich asked for a motion to approve the minutes of the September meeting. T. Schmidt moved that the minutes be approved and P. Woodrow seconded the motion. Chair L. Roehrich called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Review Top 15 Therapeutic Categories/Top 25 Drugs
B. Joyce presented the quarterly review of the top 15 therapeutic classes by total cost of claims, top 25 drugs based on number of claims, and top 25 drugs based on claims cost for the 3rd quarter of 2018.

PDL Update
A. Murphy shared with the Board all of changes made to the Preferred Drug List since the most recent 2018 version of the Preferred Drug List was posted. Notable changes included adding Rytary, Daxbia, Millipred, Millipred DP, Taperdex to the Non-Preferred Dosage Form prior authorization criteria; adding Mentax, natifine, Naftin, nystatin-triamcinolone, oxiconazole, and Oxistat to prior authorization required under the the topical antifungals PDL category; and moving Emgality, Aimovig, and Altreno to prior authorization required under the Migraine Prophylaxis PDL category.

Second Review of Glyburide and Avandia
A motion and second was made at the September meeting to place Glyburide and Avandia on prior authorization. The topics were brought up for a second review. There was no public comment. Chair L. Roehrich called for a voice vote and the motion passed with no audible dissent.

Second Review of Lucemyra
A motion and second was made at the September meeting to generate prior authorization criteria for Lucemyra. The topic was brought up for a second review. There was no public comment. Chair L. Roehrich called for a voice vote and the motion passed with no audible dissent.

Second Review of Palynziq
A motion and second was made at the September meeting to place Palynziq on prior authorization. The topics were brought up for a second review to place Palynziq into a prior authorization criteria category for Phenylketonuria with Kuvan. There was no public comment. Chair L. Roehrich called for a voice vote and the motion passed with no audible dissent.

Second Review of Roxybond & Siklos
A motion and second was made at the September meeting to place Roxybond and Siklos on prior authorization. B. Joyce spoke to the Board about the growing number of existing products with new dosage formulations of the same dose and route coming to market and the costs associated with many of these new formulations, such as Roxybond and Siklos. B. Joyce proposed that the Board allow Medicaid the ability to automatically place new formulation products on prior authorization under the Non-Preferred Dosage Formulation prior authorization criteria. The placement of new formulations on prior authorization automatically would be limited to only those agents that have the same active pharmaceutical ingredient, route, and FDA-approved indication as a currently available product. G. Kavlie made a motion to amend the Roxybond and Siklos criteria to an expanded Non-Preferred Dosage Form criteria as stated above. P. Woodrow seconded the motion. Chair L. Roehrich called for a voice vote on the motion to amend the criteria and the motion passed with no audible dissent. Chair L. Roehrich then called for a voice vote on approving the amended criteria, which passed with no audible dissent.

Annual Review of Prior Authorization Forms and Criteria
The Board reviewed all forms and criteria utilized for all medications that are currently placed on prior authorization. K. Duhrkopf of Sanofi spoke on a new indication for Dupixent for add-on therapy for moderate to severe eosinophilic asthma and asked that the Board consider adjusting eosinophil count requirements in the Dupixent prior authorization criteria. B. Joyce proposed monitoring requests for Dupixent moving forward to determine whether adjustments to the criteria should be made, to which the Board agreed. No changes were recommended during the review of the forms and criteria. A. Murphy highlighted the consolidation of multiple request forms to a "General" prior authorization request form, as well as the consolidation of many other single agent forms to single drug class specific request forms that occurred throughout the year. No changes to forms or criteria were requested or recommended by the Board. A motion was made by G. Kavlie to approve of the reviewed forms as they are, which was seconded by K. Kram. Chair L. Roehrich then called for a voice vote for approval of the reviewed forms and criteria, which passed with no audible dissent.

<u>New Business</u>
Agents for Treatment of Dry Eye Syndrome
T. DeRuiter and A. Murphy reviewed agents for treatment of dry eye syndrome with the Board. A motion was made by P. Woodrow to create this new PA criteria class and manage these medications through prior authorization. The motion was seconded by L. Schield. This topic will be reviewed at the next meeting.

Agents for Treatment of Glaucoma
T. DeRuiter and B. Joyce reviewed agents for treatment of glaucoma with the Board. A motion was made by P. Woodrow to manage the medications through prior authorization. The motion was seconded by K. Kram. This topic will be reviewed at the next meeting.

Orilissa
T. DeRuiter and B. Joyce reviewed Orilissa with the Board. A motion was made by P. Woodrow to manage the medication through prior authorization. The motion was seconded by A. Honeyman. This topic will be reviewed at the next meeting.

Vaginal Anti-Infective Agents
T. DeRuiter and B. Joyce reviewed vaginal anti-infective agents with the Board. A motion was made by G. Kavlie to manage the medication through prior authorization. The motion was seconded by P. Woodrow. This topic will be reviewed at the next meeting.

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. Laura Hill of Abbvie requested that RDUR criteria #36 be corrected to apply to patients with a Child-Pugh class of C. K. Kram moved to amend the new criteria as stated above and approve it. P. Woodrow seconded the motion. The motion passed with no audible dissent.

Adjournment and Upcoming Meeting Date
Chair L. Roehrich adjourned the meeting at 3:00 pm. The next DUR Board meeting will be held March 6, 2019 at 1:00 pm at the Heritage Center in Bismarck.